DNA Ginkgo Bioworks
- 0.841
- +0.080+10.49%
- 0.840
- -0.001-0.12%
Ginkgo Bioworks News
Ginkgo Bioworks: Addressing NYSE Standards Noncompliance
Ginkgo Bioworks Holdings Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 — William Blair Downgrades Market Perform → Underperform 03/01/2024 270.37% TD Cowen $7 → $3 M
Ginkgo Bioworks: Receives Continued Listing Standard Notice From NYSE
Ginkgo Bioworks: Receives Continued Listing Standard Notice From NYSE
Stocks With More Than 10% Short Interest - Finviz Screener
Ginkgo Bioworks Holdings First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Ginkgo Bioworks Holdings Inc (DNA) Reports Q1 2024 Results: A Comprehensive Overview
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Diodes Incorporated (NASDAQ:DIOD) fell sharply during Friday's session after the company reported worse-than-expected quarterly financial results.Diodes posted adjusted earnings of 28 cents
William Blair: Downgraded the Ginkgo Bioworks Holdings (DNA.US) rating from a unanimous market to lower than the market rating.
William Blair: Downgraded the Ginkgo Bioworks Holdings (DNA.US) rating from a unanimous market to lower than the market rating.
William Blair Downgrades Ginkgo Bioworks Holdings to Underperform From Market Perform
Ginkgo Bioworks Holdings (DNA) has an average investment rating of hold among analysts polled by Capital IQ, with price targets ranging from $1 to $3. Price: 0.8073, Change: -0.11, Percent Change: -12
Akamai Technologies Issues Weak Outlook, Joins Applied Optoelectronics, JFrog And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Friday.Shares of Akamai Technologies, Inc. (NASDAQ:AKAM) fell sharply in today's pre-market trading after
Earnings Call Summary | Ginkgo Bioworks(DNA.US) Q1 2024 Earnings Conference
The following is a summary of the Ginkgo Bioworks Holdings, Inc. (DNA) Q1 2024 Earnings Call Transcript:Financial Performance:Ginkgo Bioworks Q1 2024 revenue was $38 million, down by 18% compared to Q
Ginkgo Bioworks Holdings Q1 Loss Narrows, Revenue Drops; 2024 Revenue Outlook Slashed; Cost Cuts Planned
Ginkgo Bioworks Holdings (DNA) reported a Q1 loss Thursday of $0.08 per diluted share, compared with the loss of $0.11 a year earlier. Analysts polled by Capital IQ expected a loss of $0.08. Revenue i
Ginkgo Bioworks Files to Sell 18.86M Shares for Holders
Ginko Bioworks Holdings Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Sales Results.
Ginko Bioworks Holdings Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Sales Results.
Ginkgo Bioworks Stock Falls On Disappointing Q1 Sales: 'This Trend Needs To Change'
Ginkgo Bioworks Holdings, Inc. (NASDAQ:DNA) reported its first-quarter financial results after the bell Thursday. Here's a look at the key figures from the report. The Details:Ginkgo Bioworks reported
Ginkgo Bioworks | 10-Q: Quarterly report
Earnings Flash (DNA) GINKGO BIOWORKS Posts Q1 Revenue $38M, Vs. Street Est of $46M
04:14 PM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (DNA) GINKGO BIOWORKS Posts Q1 Revenue $38M, vs. Street Est of $46M
Ginkgo Bioworks Holdings 1Q Rev $37.9M >DNA
Ginkgo Bioworks Holdings 1Q Rev $37.9M >DNA
Ginkgo Bioworks Holdings Q1 Sales $38.000M Miss $46.044M Estimate
Ginkgo Bioworks Holdings (NYSE:DNA) reported quarterly sales of $38.000 million which missed the analyst consensus estimate of $46.044 million by 17.47 percent. This is a 52.91 percent decrease over
Ginkgo Bioworks, GreenLab Launch Partnership to Produce Sugar Substitute Brazzein
Ginkgo Bioworks (DNA) and GreenLab said Tuesday they are launching a new partnership to produce the sweetener brazzein at commercial scale. Brazzein is a protein found in the fruit of the Oubli plant,
Analysis
Price Target
No Data
